Clinical Trials · NCT07411378
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Biophytis
- Enrollment
- 164
- Start date
- Jul 2026
- Locations
- See registry
- Primary endpoint
- Change from baseline in the knee extension strength at 21 weeks